EMuNI Project: Multiple Nonpharmacological Interventions
EMuNI
Efficacy of Multiple Nonpharmacological Interventions in Individuals With Subjective Memory Complaints
1 other identifier
interventional
120
1 country
2
Brief Summary
By 2030, the global prevalence of Alzheimer's Disease (AD) is predicted to reach 65.7 million worldwide. Despite extensive research efforts, a cure for AD has not been identified. Recent studies on non-demented individuals have demonstrated the importance of a healthy lifestyle (physical exercise, healthy diet) and non pharmacological interventions (diet supplements) to delay the onset of the cognitive decline (Vemuri P et al., 2012). Given that AD is a multi-factorial disorder, some multi- component interventions at early stages could be the best strategy currently available to delay the AD onset. The aim of this study is to investigate the effects of combined non-pharmacological interventions, at different levels of intensity, on cognitive performance, on basic (hippocampal, brain ventricle volumes and white matter lesions) and advanced magnetic resonance imaging (MRI) markers (Resting-state Functional MRI, Probabilistic Diffusion Tensor Tractography
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2016
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedFirst Submitted
Initial submission to the registry
December 9, 2017
CompletedFirst Posted
Study publicly available on registry
December 22, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedSeptember 14, 2021
September 1, 2021
1.4 years
December 9, 2017
September 13, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cognitive functions
Neuropsychological test performances
12 months
Secondary Outcomes (3)
Basic imaging marker 1
12 months
Basic imaging marker 2
12 months
Basic imaging marker 3
12 months
Other Outcomes (2)
Advanced imaging marker 1
12 months
Advanced imaging marker 2
12 months
Study Arms (3)
No Treatment (NT)
ACTIVE COMPARATOREducational training
Partial Treatment (PT)
EXPERIMENTALNutritional supplementation \& Counselling on a brain-healthy diet
Full Treatment (FT)
EXPERIMENTALNutritional supplementation \& Counselling on a brain-healthy diet \& Physical exercise training \& Computerized cognitive training
Interventions
Daily consumption of Tramiprosate (100 mg) for 1 year
16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
Eligibility Criteria
You may qualify if:
- age between 60 and 80 years;
- presence of memory complaints
You may not qualify if:
- objective cognitive impairment on standard neuropsychological testing;
- history of psychiatric disorders or current clinically relevant depressive or anxious symptoms;
- pacemakers, cochlear implant, metal inserts in the head or shoulders
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Brescia, 25125, Italy
Ospedale San Raffaele
Milan, 20132, Italy
Related Publications (7)
Bowman GL, Silbert LC, Howieson D, Dodge HH, Traber MG, Frei B, Kaye JA, Shannon J, Quinn JF. Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology. 2012 Jan 24;78(4):241-9. doi: 10.1212/WNL.0b013e3182436598. Epub 2011 Dec 28.
PMID: 22205763BACKGROUNDCavedo E, Galluzzi S, Pievani M, Boccardi M, Frisoni GB. Norms for imaging markers of brain reserve. J Alzheimers Dis. 2012;31(3):623-33. doi: 10.3233/JAD-2012-111817.
PMID: 22672878BACKGROUNDErickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3017-22. doi: 10.1073/pnas.1015950108. Epub 2011 Jan 31.
PMID: 21282661BACKGROUNDLampit A, Hallock H, Valenzuela M. Computerized cognitive training in cognitively healthy older adults: a systematic review and meta-analysis of effect modifiers. PLoS Med. 2014 Nov 18;11(11):e1001756. doi: 10.1371/journal.pmed.1001756. eCollection 2014 Nov.
PMID: 25405755BACKGROUNDSperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
PMID: 21514248BACKGROUNDVemuri P, Lesnick TG, Przybelski SA, Knopman DS, Roberts RO, Lowe VJ, Kantarci K, Senjem ML, Gunter JL, Boeve BF, Petersen RC, Jack CR Jr. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. Ann Neurol. 2012 Nov;72(5):730-8. doi: 10.1002/ana.23665.
PMID: 23280791BACKGROUNDRolandi E, Dodich A, Mandelli S, Canessa N, Ferrari C, Ribaldi F, Munaretto G, Ambrosi C, Gasparotti R, Violi D, Iannaccone S, Marcone A, Falini A, Frisoni GB, Galluzzi S, Cerami C, Cavedo E. Targeting brain health in subjective cognitive decline: insights from a multidomain randomized controlled trial. Aging Clin Exp Res. 2025 May 14;37(1):151. doi: 10.1007/s40520-025-03062-z.
PMID: 40366507DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Enrica Cavedo, PhD
IRCCS Centro San Giovanni di Dio Fatebenefratelli
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 9, 2017
First Posted
December 22, 2017
Study Start
January 1, 2016
Primary Completion
June 1, 2017
Study Completion
June 1, 2018
Last Updated
September 14, 2021
Record last verified: 2021-09